Charles L. Loprinzi, MD, of the Mayo Clinic, discusses olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).
Anthony L. Back, MD, of Seattle Cancer Care Alliance, summarizes a general session on best practices and novel tools for enhancing communication between patients and oncology providers (Abstracts 8,9, 39).
Given the challenges of recruiting patients for palliative care studies, Eric Roeland, MD, of the University of California, San Diego, discusses a way to increase the participation of those with cachexia, with the hope of improving treatment (Abstract 67).
Vicki Jackson, MD, MPH, of Massachusetts General Hospital, summarizes her keynote lecture (plenary talk).
Eduardo Bruera, MD, of The University of Texas MD Anderson Cancer Center, discusses exciting developments in the assessment and management of cachexia, as well as a number of emerging pharmacologic and nonpharmacologic interventions (Abstract 67).
Judith Paice, PhD, RN, of Northwestern University, reviews the current principles on assessing and treating neuropathic pain in cancer.
